Vital Signs - Healthcare News - The Analysts Perspective - May Issue

Regular Price: USD 450.00

Special Price USD 405.00

10% OFF

* Required Fields

Regular Price: USD 450.00

Special Price USD 405.00


Be the first to review this product

This issue of Vital Signs, released on June 2, 2014, discusses the latest strategy surrounding mega deals in the pharma/biotech industry, Eurofins agreement to acquire ViroCor-IBT Laboratories, Qiagen's acquisition of BIOBASE, and the FDA's latest announcement on regulatory requirements for biosimilars.

Table of Contents

Vital Signs - Healthcare News - The Analyst's Perspective - May IssueVital Signs - May 2014This week's issue

Related Research

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.